Work

A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.561

Authors: Saby George, Laurie Herbst, Marcus Sikorski, Ann Marie Diraddo, Gissou Azabdaftari, Charles Roche, Eric Kauffman, Qiang Li, Thomas Schwaab, Ellis Glenn Levine, Roberto Pili, Gurkamal S. Chatta, Leonard Joseph Appleman, Adrienne Groman, Rahul Atul Parikh, Alan Hutson

Institutions: Roswell Park Comprehensive Cancer Center, Indiana University School of Medicine, Virginia Mason Medical Center, University of Pittsburgh Medical Center, The University of Kansas Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921513561

Cites:

Cited by: 3

Related to: 10